Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arfolitixorin in First-line Metastatic Colorectal Cancer
NCT06922383Phase 2Recruiting
- Sponsor
- Isofol Medical
- Start
- Apr 2025
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of arfolitixorin in colorectal cancer (metastatic) (mCRC) (3 arms), sponsored by Isofol Medical. Primary endpoints: Adverse Events at 24 months, Objective Response Rate at 11 months and 1 more. Started Apr 2025; status: recruiting.
02
Drugs
arfolitixorin
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT06922383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06922383.